Quick Answer
Passage BIO, Inc. reported Stockholders Equity of $18.75 million for fiscal year 2025.
Passage BIO, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $18.75M | -69.4% |
| 2024 | $61.26M | -45.0% |
| 2023 | $111.28M | -44.7% |
| 2022 | $201.37M | -36.8% |
| 2021 | $318.66M | +4.6% |
| 2020 | $304.71M | +641.7% |
| 2019 | -$56.25M | -362.1% |
| 2018 | -$12.17M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $31.12M | -57.2% | -18.7% |
| June 30, 2025 | $38.26M | -57.8% | -18.1% |
| March 31, 2025 | $46.71M | -55.5% | -23.8% |
| December 31, 2024 | $61.26M | -45.0% | -15.8% |
| September 30, 2024 | $72.72M | -42.4% | -19.7% |
| June 30, 2024 | $90.56M | -39.8% | -13.7% |
| March 31, 2024 | $104.88M | -38.4% | -5.8% |
| December 31, 2023 | $111.28M | -44.7% | -11.9% |
- Passage BIO, Inc. showed a decrease of -69.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Passage BIO, Inc.’s stockholders equity has grown by 254.1% (from -$12.17 million to $18.75 million).
- The most recent figure is from Passage BIO, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: